Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Long-Term Deferred Tax (2019 - 2020)

Celldex Therapeutics (CLDX) has 1 years of Long-Term Deferred Tax data on record, last reported at $70.0 million in Q4 2019.

  • For Q4 2019, Long-Term Deferred Tax changed N/A year-over-year to $70.0 million; the TTM value through Dec 2019 reached $70.0 million, changed N/A, while the annual FY2019 figure was $70.0 million, N/A changed from the prior year.
  • Long-Term Deferred Tax reached $70.0 million in Q4 2019 per CLDX's latest filing.
  • Across five years, Long-Term Deferred Tax topped out at $70.0 million in Q4 2019 and bottomed at $70.0 million in Q4 2019.